65 related articles for article (PubMed ID: 11680978)
1. [Feasibility of early tapering and discontinuation of cyclosporine to intensify the graft-versus-leukemia effect in patients with advanced hematologic neoplasms].
Fujimaki K; Fujisawa S; Aotsuka N; Saito K; Kanamori H; Matsuzaki M; Takahashi S; Okamoto S; Sakamaki H; Maruta A
Rinsho Ketsueki; 2001 Sep; 42(9):680-4. PubMed ID: 11680978
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.
Abraham R; Szer J; Bardy P; Grigg A
Bone Marrow Transplant; 1997 Nov; 20(9):773-7. PubMed ID: 9384480
[TBL] [Abstract][Full Text] [Related]
4. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
5. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
6. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
7. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.
Schwinghammer TL; Bloom EJ; Rosenfeld CS; Wilson JW; Przepiorka D; Shadduck RK
Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
9. [Outcomes of 50 leukemia patients who received bone marrow transplants from unrelated donors].
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato H; Hayakawa M; Kato C; Yamaguchi T; Kamiya Y; Yanada M; Morishima Y
Rinsho Ketsueki; 1998 Jul; 39(7):473-80. PubMed ID: 9750453
[TBL] [Abstract][Full Text] [Related]
10. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
11. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
13. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
[TBL] [Abstract][Full Text] [Related]
14. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
15. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
17. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
[TBL] [Abstract][Full Text] [Related]
19. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre.
Bradstock KF; Hertzberg MS; Kerridge IH; Svennilson J; McGurgan M; Huang G; Antonenas V; Gottlieb DJ
Intern Med J; 2006 Jun; 36(6):355-61. PubMed ID: 16732860
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
Yakoub-Agha I; Mesnil F; Kuentz M; Boiron JM; Ifrah N; Milpied N; Chehata S; Esperou H; Vernant JP; Michallet M; Buzyn A; Gratecos N; Cahn JY; Bourhis JH; Chir Z; Raffoux C; Socié G; Golmard JL; Jouet JP;
J Clin Oncol; 2006 Dec; 24(36):5695-702. PubMed ID: 17116940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
